Answers are grounded in this paper and cite their sources.
Androgenetic alopecia (AGA) is the most prevalent form of hair loss worldwide, yet effective treatment remains challenging due to the limited skin permeability of conventional therapeutics and the systemic adverse effects of existing pharmacotherapies. Herein, we report a minimally invasive, dissolvable microneedle (MN) platform (Cur@ZnMOF/MN) that delivers curcumin (Cur) encapsulated within an all-bioactive ginsenoside Rg1-zinc metal–organic framework (ZnMOF) for localized pathological follicular microenvironment remodeling. The ZnMOF nanocarrier is constructed exclusively from zinc ions and ginsenoside Rg1, ensuring that each structural component actively contributes to therapeutic efficacy, while enabling sustained curcumin release. In vitro, Cur@ZnMOF effectively scavenges reactive oxygen species, suppresses dihydrotestosterone (DHT)-induced inflammatory cascades, and restores dermal papilla cell (DPC) viability and migratory function. Mechanistically, the platform attenuates DHT-triggered TGF-β inhibitory signaling, thereby reactivating the pro-regenerative Wnt/β-catenin pathway. In a murine AGA model, topical application of Cur@ZnMOF/MN significantly accelerated hair regrowth, increasing follicular depth, upregulating Ki67 and β-catenin expression, and promoting hair shaft elongation compared to monotherapy controls. By integrating targeted transdermal delivery with a fully bioactive nanotherapeutic system, this strategy offers a multi-target approach to reverse follicular miniaturization, providing a highly promising and clinically translatable paradigm for AGA management.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: